Sanofi SA (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 223   

Articles published

SNY 51.75 -0.01 (-0.02%)
price chart
GlaxoSmithKline plc (ADR), Merck & Co., Inc., Pfizer Inc., Sanofi SA (ADR ...
Home > GlaxoSmithKline plc (ADR), Merck & Co., Inc., Pfizer Inc., Sanofi SA (ADR): Are Big Pharma Stocks In Trouble?
Sanofi SA (ADR) Reports Positive Cardiovascular Safety Results For Diabetes ...
Sanofi SA (ADR) (NYSE:SNY) announced Thursday positive results for its diabetes drug Lyxumia from a Phase III study evaluating the cardiovascular risks of the said drug.
Sanofi SA (SNY) Q4 Earnings Preview
Sanofi SA (ADR) (NYSE:SNY) is scheduled to announce its financial results for the fourth quarter of fiscal year 2014 (4QFY14) on Thursday, February 5 before the market opens.
Sanofi SA (ADR): Differing Regulatory Decisions Harm Global Drug Research
The marked difference in the timings of regulatory decisions worldwide regarding new medicines is a pressing issue affecting the profitability of pharmaceutical research, as discussed by Elias Zerhouni, head of research at Sanofi SA (ADR) (NYSE:SNY) on ...
Sanofi (SNY) Stock: One Big Bet on Diabetes Drugs
Sanofi SA (ADR) (NYSE:SNY) the $130 billion French drug manufacturer, is trying desperately to maintain its position as a leader in diabetes drugs.
Eli Lilly and Co Poses Threat To Sanofi SA (ADR) With Biosimilar Insulin  Bidness ETC
Sanofi SA (ADR) (NYSE:SNY) can sell Lantus: approved by US  Investor Wired
Sanofi SA (ADR) (SNY) Launches Inhaled Insulin Afrezza
Sanofi SA (ADR) (NYSE:SNY) has launched its inhalable insulin Afrezza in the US, the company announced before the US markets opened for trading Tuesday.
Whistleblower Lawsuit Accuses Sanofi SA (SNY), Ousted CEO Of Kickback ...
Sanofi SA (ADR) (NYSE:SNY) has found itself caught in a whistleblower lawsuit, where a former employee is accusing the company of funneling $34 million in kickbacks and incentive payments to various doctors and pharmacies, influencing them to prescribe ...
Related articles »  
Sanofi SA (ADR) (NYSE:SNY) Gets Approval From Japanese Ministry For ...
Sanofi SA (ADR) (NYSE:SNY)-owned Gnezyme, has finally received approval from the Japanese government for the use of Cerdelga, the oral treatment for Gaucher disease type 1. The country's Ministry of Health, Labor and Welfare has approved the use of ...
Sanofi SA (SNY) Continues Search For Head; Smith & Nephew (SNN) CEO Out ...
In an employee meeting, Smith & Nephew plc (ADR) (NYSE:SNN) Chief Executive Olivier Bohuon dismissed rumors of his plans to leave the medical-device maker to join Sanofi SA (ADR) (NYSE:SNY), as per reports from Bloomberg. This implies that Sanofi, ...
Related articles »  
Sanofi SA (SNY) Outsources Research Facility To Evotec (EVTCY)
Sanofi SA (ADR) (NYSE:SNY) is reportedly in exclusive talks with Hamburg-based Evotec AG (ADR) (OTCMKTS:EVTCY) to transfer its research operations in Toulouse, France to the German drug-maker.
Related articles »